No named dietary pattern has been shown superior to the others on the outcomes people actually care about — length of life, heart attacks, strokes, incident diabetes — once a diet clears a floor of basic adequacy. That is not a gap waiting to be filled. Above the floor the question has been tested at scale, and the honest answer is that the patterns come out close to the same. This is a no-meaningful-difference finding, not a shrug — a stronger statement than we don’t know.
So the useful instrument is not a ranking but two screens, and only one of them works in the direction people expect. You can refute a diet — show it starves the body of an essential nutrient or of energy — but you cannot verify one: no pattern earns a gold star on hard outcomes. Below the floor the verdict is clear; above it, the label stops carrying the decision. What small real differences remain travel not with the name on the plate but with its components, its total energy, and how well it is sustained — and every one of them is trivial next to the move from a person’s own current baseline. The label is the axis people argue about and the least likely to be doing the work.
A few genuine signals do sit above the near-null, and the body names them. But the overall confidence here is low and the loop is open: nothing in this guide has been graded against a realized outcome. For most people, the most useful message is that the choice between reasonable patterns is not where their health is won or lost.
Split which diet is best? into four questions
“Which diet is best?” is not one question — it is four, and they answer to different evidence. Asked as a single question it cannot be answered well, because a good answer to one part is silent on the others. Before ranking anything, separate them:
- (a) Superior on what — and is it even a difference? A claim that one pattern beats another has to name the outcome: a hard, patient-important outcome (a heart attack, a death, a diabetes diagnosis) or a surrogate (weight, blood pressure, LDL) standing in for one -> Surrogate Outcomes. And it has to name the evidence state, because benefit, harm, no-meaningful-difference, and insufficient evidence are four distinct verdicts and the last two are constantly confused. No difference found — measured, at scale, and come back flat — is a result; not studied is an admission. They license opposite actions.
- (b) Known how well? The same claim graded off a randomized trial and off a confounded observational cohort is not the same claim -> Rating Certainty of Evidence. Diet is where this bites hardest: intake is self-reported, and the measurement error is large enough to flatten a real gradient into a null or to manufacture one that is not there -> Measurement Error in Dietary Assessment.
- (c) The difference travels with what? If two patterns do differ, the difference rides on some axis — the label itself, the shared components the patterns hold in common, total energy and adiposity, or adherence. The label is the one people fight about and, as the body will show, the least likely to be carrying the effect -> Is the Food Category Doing Any Work.
- (d) Big compared to what? A between-pattern difference can be real and still trivial next to the pattern-vs-baseline move — the gap from what a person eats now. A one-kilogram edge of one diet over another is a rounding error beside the change from either to a person’s current plate.
Answer these together and you get noise; answer them in order and the picture resolves. Separated this way, the first move is not to rank the diets but to see which ones fail outright — so start with the floor.
Start with the floor: you can refute a diet, not verify one
The screen that works is negative. Verifying a diet — proving that a named pattern delivers a long, healthy life — would take a randomized whole-diet trial run for decades on hard outcomes, and for almost every pattern that trial does not exist and never will: you cannot blind a diet, randomize a lifetime, or measure intake cleanly -> Measurement Error in Dietary Assessment. So the screen that carries weight runs the other way — a floor that rules a diet OUT, not a scale that ranks it up. A diet can be refuted; it cannot be certified.
Build the floor from the two least-contested harms, and nothing else. A diet fails the floor if it does either of two things:
- It starves the body of an essential nutrient. Frank deficiency is evidenced harm, read directly off repletion: correcting iodine deficiency raises child IQ by roughly 6.9 to 10.2 points (Bougma et al., 2013), and the same repletion logic holds for iron, folate and the rest -> Deficiency Repletion vs Enhancement. A plate that cannot cover the essentials is harmful on the clearest evidence nutrition has.
- It runs a gross energy imbalance. A sustained large surplus or deficit is harmful independent of any nutrient debate.
These two screen out the deficient-by-design plates — all-fast-food, butter-only, strict carnivore judged on adequacy — without appeal to a single contested nutrient. That restraint is the whole point of the floor, and it is easy to lose.
Clearing the floor makes a diet admissible, not good. Passing means only that the diet is not disqualified; it earns no recommendation. Reading “meets basic adequacy” as “optimal” is the same category error as reading an RDA — a deficiency floor set to prevent shortfall — as a target to optimize toward -> The Descriptive-Normative Category Error. The floor is a gate, not a grade.
And “butter-only is bad” is a deficiency-and-energy verdict, not a verdict on saturated fat. The floor rejects a butter-only diet because it cannot cover essential nutrients — not because of its saturated-fat load, which is a genuinely contested component, not a settled harm. The trial evidence for reducing saturated fat clears the null on exactly one soft composite outcome — cardiovascular events, at RR 0.83, and that estimate is itself contested (comparator contamination, trial-quality sensitivity) — while all-cause mortality is a well-graded null at RR 0.96 (Hooper et al., 2020) -> Does Reducing Saturated Fat Reduce Cardiovascular Events. A component that unsettled has no business in a screen meant to be uncontestable. The moment the floor is built from a contested component, it stops being a floor and becomes a smuggled claim that some patterns are simply better — the exact move this structure exists to avoid; saturated fat is weighed later, as a component among components, not here as a pass/fail line.
Clear the floor and the picture changes: among diets that pass, the label stops doing work.
Weigh the passing patterns head-to-head: the label barely moves the needle
Among the diets that pass, the brand stops doing work — and one study ran the whole comparison at once to show it. Ge 2020 is a network meta-analysis of 121 randomised trials and 21,942 overweight or obese adults, placing 14 branded named diets (Atkins, DASH, Zone, Ornish, Mediterranean, Weight Watchers and the rest) and three macronutrient patterns (low-carbohydrate, low-fat, moderate-macronutrient) into one network, ranked on weight and five cardiovascular risk factors at 6 and 12 months, GRADE-rated throughout, searched to September 2018 (Ge et al., 2020). It is the field’s comparative-effectiveness island: it answers which diet wins directly, rather than one pairwise contrast at a time.
One caveat governs everything that follows: every endpoint here is a surrogate — weight, systolic and diastolic blood pressure, LDL, HDL, C-reactive protein — measured over 12 months at most, with no hard endpoint (mortality, heart attack, stroke, incident diabetes) anywhere in the network (Ge et al., 2020). Ge closes the between-diet and durability questions; it says nothing about events -> Surrogate Outcomes.
Read Ge on two tiers, because the tiers point opposite ways. The first tier is each pattern against doing nothing: at 6 months low-carbohydrate and low-fat produce near-identical weight loss (4.63 vs 4.37 kg versus usual diet, both moderate certainty) and near-identical blood-pressure falls (SBP 5.14 vs 5.05 mmHg; DBP 3.21 vs 2.85 mmHg), with moderate-macronutrient patterns slightly smaller (Ge et al., 2020). Ge pre-specified what counts as a meaningful gap — weight 2 kg, SBP 3 mmHg, DBP 2 mmHg, LDL 5 mg/dL (Ge et al., 2020) — and every pattern clears that bar against usual diet. That each pattern beats doing nothing is the real benefit.
The choice between them is the second tier, and it collapses: the largest low-carb-versus-moderate-macronutrient weight gap is 1.57 kg (0.86 to 2.29), below the 2 kg bar, and the Atkins-versus-Zone gap is just 1.38 kg (0.15 to 2.62) (Ge et al., 2020). Ge’s own verdict: «Differences between diets were typically small to trivial and often based on low certainty evidence» (Ge et al., 2020).
This is the answer to the magnitude question, and it decides the section. The gap between any two named diets is small and trivial next to the gap from a person’s own baseline: the move from doing nothing is roughly three times the widest distance between two brands. A reader agonising over which label to pick is optimising the smaller of two numbers. Ge draws the practical consequence directly — «people can choose the diet they prefer from among many of the available diets … without concern about the magnitude of benefits» (Ge et al., 2020).
By 12 months even the first-tier benefit is mostly gone. «At 12 months the effects on weight reduction and improvements in cardiovascular risk factors largely disappear» (Ge et al., 2020) — weight loss versus usual diet falls from 4-5 kg to about 3 kg, the blood-pressure and lipid gains fade almost completely, and the between-pattern differences are negligible at that timepoint (Ge et al., 2020).
Name the evidence state precisely: this is no-meaningful-DIFFERENCE, not insufficient-evidence. The between-diet comparison was run — at scale, GRADE-rated, against a pre-specified importance bar — and came back near-null. That is a stronger and different statement than we don’t know. The distinction has a hard edge that must be held: Ge’s surrogate near-null does not refute the one whole-pattern trial on hard events (PREDIMED) or a cohort’s mortality association, because those measure different quantities on different endpoints. No difference found on surrogates over a year is not no difference on events over a decade.
A second body reaches the same verdict on the same evidence. NICE (NG246, 2025) assessed the macronutrient-defined diets and left every one of them without a recommendation; the only diet it will positively recommend is defined by energy, not macronutrient — total diet replacement at 800-1200 kcal, for 12 weeks, inside a specialist service (National Institute for Health and Care Excellence, n.d.) -> Diets for Weight Loss - What NICE Recommends. This is agreement, not independent corroboration: NICE appraises largely the same randomised-trial base Ge pools (it lists Naude 2022 among its source reviews), so a shared missing trial would move both. What the concurrence shows is that two appraisals of the same evidence both decline to rank the macronutrient label.
The label barely moves the needle partly because the label barely fixes the plate. One name spans clean and dirty versions of a diet that differ more than the labels differ from each other — a whole-food Mediterranean plate and a refined-carbohydrate one both answer to “Mediterranean.” So a label-level contrast compares two distributions that overlap heavily before any outcome is measured, and that overlap accounts for much of the near-equivalence -> Is the Food Category Doing Any Work. This is why clearing the floor makes a diet admissible, not good, and why no primitive of overall “pattern quality” is doing the work here: the finding is that the brand under-determines the plate, not that any decent pattern is the large lever.
If not the label, what carries the small differences that are real? Before naming the axis, face the harder problem the surrogate ceiling hides: the head-to-head hard-outcome trial between two named patterns cannot be run at all — so how does one get a direction from the evidence that does exist?
Get a direction where the head-to-head trial can’t be run
The between-pattern hard-outcome comparison is structurally unrunnable. A decades-long randomised trial pitting one named pattern against another on mortality and events will not be conducted, and no meta-analysis can pool trials that do not exist — Ge’s own network is surrogate-only for exactly this reason. But “no head-to-head meta-analysis” is not “no directional guidance.” Three moves extract a defensible direction from the evidence that does exist, and each is a method the corpus already holds, not a loosening of the evidence bar.
1. Emulate the trial that cannot be run. Target-trial emulation means writing down the specific randomised experiment an observational analysis stands in for — its eligibility criteria, its time-zero, and the two pattern strategies being contrasted — and then estimating that trial’s effect from cohort data under identification assumptions made explicit, instead of reading an unadjusted pattern-mortality association off a food-frequency questionnaire. This converts which pattern is healthier? from an un-anchored correlation into a stated causal contrast whose assumptions can be checked, which is what lets observational pattern data speak to direction at all. Where no coherent target trial can be written, the estimate answers no causal question. -> The Target Trial (Emulation and the Well-Defined Intervention), The Comparator Problem
2. Decompose the pattern into well-defined components. A pattern label — “vegan”, “keto”, “Mediterranean” — bundles many versions of treatment: one name covers diets differing in fibre, refined sugar, energy density, protein, and total energy. The label-level contrast is therefore ill-posed before any data arrive, because the two arms are not each a single intervention. The corpus’s resolution is to name the component and ask which axis carries the difference. Ge’s network already shows the macronutrient label carries almost nothing on surrogates, while the food-category diagnostic shows repeatedly that a nameable sub-component — energy density, cereal fibre, heme, brew method — does the work the food or pattern label gets credited with. So the directional question that is answerable is component-level, not label-level. -> Is the Food Category Doing Any Work, The Target Trial (Emulation and the Well-Defined Intervention)
3. The extremes separate even where the middle does not — and that is itself the finding. Ge fixes the middle of the pattern space (DASH versus Mediterranean versus low-carb versus Zone) as near-equivalent on surrogates, the between-label gaps sitting below the importance bar — which licenses choosing on adherence and preference rather than agonising over the brand. That near-equivalence does not extend to the extremes. A whole-food, high-fibre, low-refined pattern versus a highly-refined, energy-dense one is a component contrast the decomposition above expects to be load-bearing, and the evidence there is not symmetric with the middle.
Two guards keep this honest, and they cut in opposite directions.
The confounded-anchor trap cuts against reading the extremes off cohorts. The strong long-horizon anchors that would drive an extreme-versus-extreme ordering — Adventist-type vegetarian cohorts against a Standard American Diet — differ in far more than diet: smoking, alcohol, activity, adiposity, social cohesion all travel with the pattern. A benefit read off them and attributed to the label is the observed-healthy-population trap, where the pattern is credited for what its correlates did. The benefit may be real; its attribution to the label may not transport. This is precisely why direction is trustworthy at the component level — where a target-trial emulation can adjust for the confounder set it names — and fragile at the label level. -> Is the Food Category Doing Any Work, The Comparator Problem
The studied-data asymmetry cuts the other way, against treating all patterns as equally unknown. The data are not evenly thin across the extremes. The whole-food, mostly-plant end carries many large, long-horizon cohorts; the low-carbohydrate and carnivore end has few long hard-outcome cohorts, and those are recent, small, and self-selected. So we cannot rank the patterns is itself an average over an asymmetry — one extreme sits nearer insufficient-evidence than the other — and the honest output names which end is data-poor rather than declaring all patterns equally unadjudicated. The long-cohort anchors this reasoning would need are a named acquisition gap, not a held finding.
Together, these moves turn a shrug into a structured answer. No pattern is clearly better becomes: near-equivalent in the middle, so act on adherence; component-ordered at the extremes, so act on the measurable component rather than the label; and one extreme genuinely under-studied, so say so — all without asserting any hard-outcome pattern ranking the evidence does not license.
So apply the decomposition. Once the pattern is specified as its components, which axis actually carries the difference that is left?
The difference travels with components, energy, and adherence — not the brand
The pattern label is a container; the effect rides on what fills it. Three axes carry essentially all of the signal the named diets are credited with — the shared protective and harmful components, total energy and the adiposity it drives, and the adherence that decides how much of any of it a person actually receives. Specify those three and the brand adds almost nothing on top.
The shared components carry what signal there is
Fibre is the cleanest supporting lever, and its strongest evidence sits on its smallest effect. Highest-versus-lowest fibre intake tracks a 15-30% lower risk across the critical outcomes — all-cause mortality RR 0.85, CHD 0.76, type 2 diabetes 0.84, colorectal cancer 0.84 (Reynolds et al., 2019) — which Reynolds puts at about 13 fewer deaths per 1000 over the studies’ duration. Those numbers are observational and carry the healthy-user confound. Where fibre is tested as a dosable, blindable isolate it moves the LDL surrogate by −0.057 mmol/L per gram of viscous fibre in the practical 2-10 g/day range (Brown et al., 1999) — a real, causal, and modest effect. The causal claim is firmest exactly where the effect is smallest; the practical from-food intake target is set at its home page -> Dietary Fibre and Health.
Fruit and vegetables help, but as whole foods, not as clean fibre evidence. Higher intake tracks all-cause mortality RR 0.90 per 200 g/day (Aune et al., 2017), and the source itself blocks attributing that to any one constituent: it runs through fibre, vitamin C, carotenoids, potassium, flavonoids and other compounds acting together. So F&V corroborate the direction of the fibre story without isolating it — the observed-healthy-population rule in miniature.
Nuts carry a real signal that plateaus early — the curve shape is the actionable part. Per 28 g/day, nut intake tracks all-cause mortality RR 0.78 (0.72-0.84) and CHD 0.71 (0.63-0.80), but the benefit plateaus by roughly 15-20 g/day — a small handful buys most of it, and more adds little (Aune et al., 2016). The evidence is observational (no whole-food RCT), so rank it a moderate lever; the decision-relevant feature is the knee, not the point estimate.
The load-bearing move: name the component, because the category label is often decorative.
-
Grains — the “whole” is not the work, the cereal fibre is. Whole-grain intake tracks all-cause mortality RR 0.83 (0.77-0.90) per 90 g/day, with benefit still climbing to 210-225 g/day (Aune et al., 2016a). But refined grains show no measured harm on hard outcomes — RR 1.00 (0.98, 1.01) for both cardiovascular events and type 2 diabetes, graded
No association · Moderate(Scientific Advisory Committee on Nutrition, 2015) — and SACN attributes the whole-grain signal to its cereal-fibre component, not the milling status (Scientific Advisory Committee on Nutrition, 2015). The refined-versus-whole contrast is compositional, not a demonstrated harm of refinement. -> Whole Grains Refined Grains and Pulses -
Meat — the boundary is processed versus unprocessed, not red versus white. Processed meat carries a firm colorectal-cancer signal, RR 1.16 (1.08-1.26) per 50 g/day; red meat’s is RR 1.12 (1.00-1.25) per 100 g/day, its lower bound touching the null and the pooled estimate not statistically significant (World Cancer Research Fund International, 2018). The candidate driver is heme iron, intrinsic to red meat regardless of curing, not its saturated fat — saturated fat shows no effect on colorectal carcinogenesis (Bastide et al., 2011). On lipids the within-pattern lever is the protein source, a separate axis from saturated fat: pooled across 36 substitution trials, replacing red meat with high-quality plant protein lowers LDL-C by +0.198 mmol/L (95% CI 0.065-0.330) (Guasch-Ferré et al., 2019) — a surrogate (lipid) endpoint, no CVD events, isolating one component’s contribution without moving the whole-pattern verdict.
-> Red and Processed Meat and Cancer, Lean Red Meat and Atherogenic Lipoproteins
-
Saturated fat is contested and replacement-framed — the substitution sets the sign, so it is never a floor. On LDL the exchange is what matters, high certainty: −0.055 / −0.042 / −0.033 mmol/L per 1% of energy moved to PUFA / MUFA / carbohydrate (World Health Organization, 2023). On events the trial evidence is the contested one weighed in the floor section above (events RR 0.83, all-cause null RR 0.96) -> Does Reducing Saturated Fat Reduce Cardiovascular Events. What the trials cannot separate is saturated-fat harm from replacement benefit, so avoid SFA is not what the evidence licenses; replace SFA with PUFA or whole foods is (Astrup et al., 2020). -> Saturated Fat Intake and Replacement
-
Sodium is a blood-pressure component, and briefly. A modest reduction lowers systolic BP by about −3.4 mmHg at high certainty (World Health Organization, 2012), larger in hypertensives than normotensives (−5.39 vs −2.42 mmHg) (He et al., 2013); the hard-outcome evidence stays very low certainty. -> Sodium Intake and Blood Pressure
And run the decomposition inward: within a winning diet-quality score, no single component carries it. PURE’s unweighted count of six protective foods — fruit, vegetables, nuts, legumes, fish and mainly whole-fat dairy — separates its extremes by mortality HR 0.70 (0.63-0.77) (Mente et al., 2023), about 6% lower major CVD and 8% lower mortality per quintile, and adding or swapping red meat or whole grains left the predictive value neither stronger nor weaker (Mente et al., 2023). The aggregate pattern is the decision unit; the components are near-substitutable within it. The guard is real: swap-invariance in a healthy-user-confounded score (the crude signal roughly halves under adjustment, HR 0.54 -> 0.70) is not evidence that each food is causal. The narrow, defensible reading is do not over-specify which protective foods — not any of them is proven to work. -> Diet Quality Scores and Cardiovascular Risk
Processing is a component axis too, but keep its certainty straight. At matched composition — calories, energy density, macronutrients, sugar, sodium and fibre held level — an ultra-processed diet still drove 508 kcal/day of extra ad libitum intake and 0.9 kg of weight gain in an inpatient crossover (Hall et al., 2019), through energy density, eating rate and protein dilution. That is a real processing effect on the energy-intake surrogate at moderate certainty; whether it transmits to the hard outcomes the observational literature associates with ultra-processed food stays low-certainty. The actionable targets are the measurable properties, not the label. -> Ultra-Processed Food and Health Outcomes, Is the Food Category Doing Any Work
Total energy and adiposity are the other axis
Weight loss is a proven lever for glycaemia, T2D remission, MASLD and function — but unproven for hard cardiovascular events. The largest, longest lifestyle trial, Look AHEAD, was null on its cardiovascular composite, HR 0.95 (0.83-1.09) (Look AHEAD Research Group, 2013), and the 54-RCT meta-analysis generalizes that null: CV events RR 0.93, non-significant, while all-cause mortality falls RR 0.82 — about 6 fewer deaths per 1000, high quality, and by a route that is not the heart (Ma et al., 2017). Where weight loss plainly delivers is elsewhere: an energy-restricted programme put 46% of short-duration T2D patients into remission (Lean et al., 2018). -> Does Weight Loss Reduce Cardiovascular Events
And “which macronutrient split” is largely the wrong axis for the weight itself. At equal calories with protein matched, the macronutrient source confers no body-fat or expenditure advantage: pooled isocaloric feeding found energy expenditure and fat loss slightly greater on lower-fat diets (+26 kcal/day, +16 g/day) — the opposite sign to the carbohydrate-insulin model’s prediction, and small enough to be physiologically meaningless (Hall & Guo, 2017). The free-living test agrees: DIETFITS found a between-group difference of 0.7 kg at 12 months with no diet-by-insulin-secretion interaction (P = .47) and no diet-by-genotype interaction (P = .20) [@gardner2018]. So weight moves through total energy and adherence, not through a privileged carbohydrate ratio. Cutting carbohydrate is one route to eating less, not a distinct metabolic channel. -> What Drives Fat Gain - Energy Balance vs the Carbohydrate-Insulin Model
Adherence is part of the effect
Realized effect is efficacy times adherence, and the trials show the second term dominating. Look AHEAD’s arms converged from a 7.9-percentage-point weight gap at one year to 2.5 points at study end — a modest sustained difference, not big-loss-versus-none (Look AHEAD Research Group, 2013). DIETFITS’ near-tie carries the same message: two high-quality diets pursued to a 0.7 kg difference.
Across the named-diet literature, the 12-month decay is an effect-times-adherence phenomenon, not a biological wall. Ge’s network meta-analysis found the six-month benefits of every macronutrient pattern largely gone by twelve months, and reads its own estimates accordingly — adherence was generally unreported and probably low by twelve months, so the numbers describe average adherence and full adherence would likely yield larger effects (Ge et al., 2020). The decision consequence is direct: a smaller change a person sustains beats a larger one they abandon, so between two diets that tie on physiology, the one they will actually keep wins on the term that dominates. -> Named Diet Programs Compared
Every magnitude above came with a certainty caveat attached — so how good is the evidence, pattern by pattern?
Grade each island on its own endpoint
Sorted by study design, the literature is four islands that do not carry equal weight — they answer different questions on different endpoints, so a weak grade on one does not overturn a signal on another. Read each on the endpoint it actually measured, and keep the surrogate islands apart from the hard-outcome one.
Two whole-pattern RCTs measured hard events, and they split — PREDIMED found benefit, the WHI low-fat trial found none. In 7,447 high-CV-risk adults, a Mediterranean diet supplemented with olive oil or nuts cut the composite of MI, stroke and CV death: combined HR 0.70 (0.55-0.89), a ~30% relative and 1.7-2.1 percentage-point absolute reduction over ~5 years (Estruch et al., 2018). The composite is carried by stroke (HR 0.58); MI and CV death are individually non-significant, and all-cause mortality is null (0.98). The absolute benefit is real because baseline risk was high, not because the relative effect was large -> Baseline Risk and the Relative-Absolute Split. Internal validity is RCT-with-repair: the 2013 report was withdrawn after Carlisle flagged non-random baseline distributions, and the 2018 re-analysis re-estimated with propensity scores over 30 covariates. The result held, but the discount is real, so the finding is held at medium confidence and not waved through because it is favourable (Estruch et al., 2018).
The WHI Dietary Modification trial is the second whole-pattern RCT on hard events, and it is null. It randomized 48,835 postmenopausal women to a low-fat pattern — total fat toward 20% of energy, more vegetables, fruit and grains — versus no diet change over a mean 8.1 years, and cutting total fat did not move coronary heart disease: CHD HR 0.97 (0.90-1.06), with stroke (1.02) and total CVD (0.98) equally null (Howard et al., 2006). But this is a no-meaningful-effect on the tested contrast, not a refutation of diet-heart: the trial changed total-fat quantity — its calories displaced mainly by refined carbohydrate, not fat quality — by a diluted dose (the achieved between-arm fat gap reached only ~70% of design), and was underpowered for the small LDL change it produced (Howard et al., 2006). So the two hard-outcome RCTs do not truly clash: PREDIMED tested a protective-foods pattern in high-risk adults and cut events; WHI tested a fat-to-carbohydrate swap and, by its own design, could not have -> Low-Fat Dietary Pattern and Cardiovascular Disease.
Ge grades the comparison between patterns well, but is silent on events. Its 121-RCT network meta-analysis is moderate-certainty on weight and cardiovascular risk factors — yet every endpoint is a surrogate measured at <=12 months (Ge et al., 2020). It closes the between-diet and durability gaps; it says nothing about mortality, MI or stroke -> Surrogate Outcomes.
DASH is a surrogate island with no hard endpoint at all. Siervo pooled 20 short RCTs: DASH vs control SBP -5.2 mmHg and DBP -2.6 mmHg, with a small LDL/total-cholesterol co-benefit and null glucose, HDL and triglycerides (Siervo et al., 2014). The DASH -> events step rides on the general BP-lowering-to-events chain, not on DASH trials. Name the gap: the Appel/Sacks DASH-Sodium feeding trials are not held separately, so the fabric cannot yet grade DASH’s BP effect independent of the weight and sodium changes that travel with the pattern.
The vegetarian island is now broader than one cohort — but the ceiling has not moved. The single-cohort detail comes from the Adventist Health Study 2, where all vegetarians combined carried an all-cause HR 0.88 — roughly one fewer death per 1,000 person-years in absolute terms (Orlich et al., 2013). A gold-tier umbrella of 21 systematic reviews now pools the multi-cohort picture and grades each arm with GRADE: a vegetarian (including vegan) pattern carries CVD incidence RR 0.85 (0.79-0.92) and CHD incidence RR 0.79 (0.71-0.88), and these are the review’s strongest arms — «only lower CVD and CHD incidence had moderate certainty evidence» (Landry et al., 2024), while every mortality arm stays low certainty and total stroke comes back null.
But breadth is not independence, and the umbrella inherits the confound rather than escaping it. The 21 reviews re-pool a shared cohort base — of twelve stroke cohorts «All twelve primary studies were reported in Dybvik et al.» (Landry et al., 2024) — so the count is coverage, not 21 independent replications, and the Adventist and EPIC-Oxford cohorts that dominate this literature carry the healthy-adherer bundle (leanness, non-smoking, abstinence) into every pool.
Orlich’s authors say so plainly: «Potential for uncontrolled confounding remains» (Orlich et al., 2013). So the direction is well-supported — moderate certainty for incidence — while the causal step past the confound is unmade: a pattern association is not evidence for any one of its components -> Is the Food Category Doing Any Work, Vegetarian Dietary Patterns and Mortality. Name the stake symmetrically — the umbrella was «supported by the Academy of Nutrition and Dietetics… Vegetarian Nutrition Dietetic Practice Group» (Landry et al., 2024), which earns the same appraisal bar as an industry-funded meat paper, no more -> Which Objective Moved This Recommendation.
One nutrient-floor caveat is specific to this island: B12. A vegetarian or vegan plate carries essentially no B12, and biochemical depletion is common — reported prevalence ran «from about 11 to 90%» across studies (Pawlak et al., 2013), the wide band partly an artifact of which cutoff each study chose, because serum B12 is an unreliable marker and «MMA and holo-TCII are the most accurate» (Pawlak et al., 2013). But keep the evidence state straight: this caveats a marker, not a demonstrated harm. In the one study that looked, «none of the vegetarians included in their study had clinical symptoms despite the fact that about two-thirds of the sample had B12 depletion or deficiency» (Pawlak et al., 2013). So biochemical deficiency is prevalent and real; whether it transmits to clinical harm in this stratum is insufficient evidence — not benefit, harm, or null — and the practical fix is cheap: a supplement closes the gap.
-> Vitamin B12 Status in Vegetarian and Vegan Diets
Two discounts sit under all four islands. Dietary measurement error flattens every cohort read — reported energy runs, on average, 34% below doubly-labelled-water expenditure in adults 16-64 (Scientific Advisory Committee on Nutrition, 2015) -> Measurement Error in Dietary Assessment. And the surrogate-versus-hard-outcome line holds throughout: a marker moved is a recommendation earned only where its transmission to a patient-important outcome is itself evidenced -> Surrogate Outcomes, Rating Certainty of Evidence.
Two of these islands carry a real, decision-relevant signal, and one carries a real stratum-specific harm.
Weigh the three findings that clear the near-null
Three findings sit genuinely above the surrogate near-null, and each earns its place on its own evidence — so keep them apart rather than folding them into one “some diets are better” claim.
Mediterranean’s residual signal
Two unrelated designs single out the Mediterranean pattern, and that is exactly why they are two flags rather than one finding counted twice. Ge’s network meta-analysis finds that «Estimated effects at the 12 month follow-up for weight loss and cardiovascular risk factor improvements diminished for all popular named diets, except for the Mediterranean diet», which was also the most effective named diet for LDL reduction at moderate certainty (Ge et al., 2020). PREDIMED separately cut hard events by ~30% at high baseline risk (Estruch et al., 2018). These are different quantities on different endpoints — Ge measures the LDL surrogate over <=12 months, PREDIMED measures events over ~5 years — so they do not corroborate each other’s number; they independently point at the same pattern. Do not sum them into a single “Mediterranean wins” magnitude.
Energy deficit and diabetes remission
In type-2 diabetes, a large energy deficit can drive remission — and the lever is the deficit, not the carbohydrate. DiRECT delivered 46% remission versus 4% in controls (OR 19.7), and remission rose monotonically with weight lost: 0% among those who gained weight, 7% at 0-5 kg, 34% at 5-10 kg, 57% at 10-15 kg, and 86% at >=15 kg lost (Lean et al., 2018). That dose-response ladder is the decision-relevant feature — the deeper the deficit, the higher the remission rate. The gold-tier umbrella review places total-diet-replacement remission at a GRADE-high median of 54% (Churuangsuk et al., 2021).
The composition does not carry it: DiRECT produced that result on an 825-853 kcal, 59%-carbohydrate formula — the opposite of a low-carbohydrate diet — so it is the energy-delivery format (VLED / formula) that separates the diets, not their macronutrient split (Churuangsuk et al., 2021). A low-carbohydrate route to the same weight loss exists but is weakly grounded: Goldenberg’s remission advantage (RD 0.32) holds only under the definition that allows medication to continue, and is non-significant under the stricter medication-free definition (Goldenberg et al., 2021), while the umbrella records that «No RCT has evaluated LCDs/ketogenic diets for type 2 diabetes remission» (Churuangsuk et al., 2021). So read carbohydrate restriction as one route to the weight loss that drives remission, not a separate metabolic channel -> Diets for Weight Management in Type 2 Diabetes, Carbohydrate Restriction and Type 2 Diabetes Remission.
The apoB hyper-responder and low-carb (route c)
A low-carbohydrate pattern ties on weight and blood pressure, but is the poorer choice for one stratum — the apoB hyper-responder. On weight the near-equivalence is confident: when trial arms are matched on energy, low-carbohydrate beats balanced-carbohydrate by only -0.48 kg with I2 = 0% (Naude et al., 2022). What does not tie for everyone is the atherogenic lipoprotein response, and Naude names the stratum: «In people with lipid disorders and variability with atherogenic lipoprotein response, caution in recommending low-carbohydrate and consequent high-fat diets is warranted» (Naude et al., 2022).
This is a genuine route-(c) contraindication, not a population-wide harm, and it bites because the cost is cumulative: ASCVD risk tracks the absolute apoB/LDL-C reduction multiplied by its duration, so run in reverse, a sustained elevation compounds over a lifetime (Ference et al., 2017). apoB is the number to watch in this stratum, because LDL-C can under-state the particle burden precisely in the insulin-resistant, hypertriglyceridemic person -> LDL ApoB and Cumulative Exposure. One bound holds the finding honest: whether deeper restriction worsens the lipid cost — the Naude-versus-Goldenberg direction clash — is an open question, not a settled gradient, because their populations and reference bands differ and the estimands do not match.
Notice which patterns generated this section — Mediterranean and total diet replacement — and which generate the most noise elsewhere.
Discount the loudest diets, and name the trade-off you can’t price
The two patterns that earned the last section — Mediterranean and total diet replacement — are not the ones you hear most about, and that inversion is the rule, not the exception.
A pattern’s popularity is evidence about the field, not about the exposure. Attention runs inverse to effect size: the settled big levers are boring, and the contested small ones generate the books, the brands, and the feeds. So the loudest named patterns — carnivore, keto, the branded programs — are precisely the ones not matched by hard-outcome evidence, while the quiet, component-rich staples (fibre, whole grains, fruit and vegetables, nuts) carried what signal there is -> Layer 1 - Ranking Interventions for a Stratum. Read the volume of noise around a diet as a fact about the market, not a reason to adopt it.
One trade-off is real but sits off the health axis: environmental load. A plant-forward pattern — and the EAT-Lancet framing built on it — carries a lower environmental footprint than a meat-heavy one, and that direction is not in doubt. But this wiki holds only health evidence: no carbon, water, or animal-welfare data, and no basis to weigh a kilogram of CO2 against a millimetre of blood pressure. Name that the trade-off exists and which way it runs, then stop — the weighting between health and environment is the person’s own, made at the point of decision, and pricing it here would be a false objectivity the evidence cannot supply.
Walk away with a floor, then a pattern you’ll keep
Clear the floor first. Two things reliably rule a diet out: it cannot supply the essential nutrients, or it pushes energy grossly out of balance. Deficiency and chronic over- or under-eating are evidenced harms, so a plate that courts either is bad by construction — this is the one screen that does real work -> Deficiency Repletion vs Enhancement. Everything past it is admissibility, not virtue: clearing the floor makes a diet allowable, not good, and “meets 100% of the RDA” is a deficiency floor read as a target, not a finish line -> The Descriptive-Normative Category Error.
Above the floor, pick the pattern you will actually keep. The brand is close to irrelevant. The patterns that pass are built from the same big rocks — fibre, whole grains, fruit and vegetables, nuts, some shift from saturated toward unsaturated fat, less free sugar, less sodium, less processed meat — and those components, together with total energy, carry what small difference there is. Between two diets you are choosing between two sets of advice at achievable adherence, and the one you will sustain wins on the term that dominates. So let your own situation set the choice: the fabric is general, but its application is personal, and the absolute benefit of any lever depends on where you personally start -> Baseline Risk and the Relative-Absolute Split.
Some choices belong with a clinician, not a search bar. A vegan needs B12. A ketogenic or carnivore pattern needs lipid and renal monitoring, and is the poorer choice for anyone whose apoB rises sharply on carbohydrate restriction — a genuine contraindication, not a general one -> Named Diet Programs Compared. Pregnancy, childhood, and a history of disordered eating each change the calculus in ways this general fabric cannot personalize. These are the strata where “pick what you’ll keep” is not the whole answer.
Name the gap plainly. No head-to-head trial has ever compared these patterns on hard outcomes — mortality, heart attacks, strokes — because such a trial is impractical to run, so the honest confidence here is low. Nothing above has been graded against a realized outcome; the loop is open. The verdict is not that diet does not matter, but that above a floor of adequacy the brand matters far less than the marketing implies — and far less than whether you keep it.
Evidence box
Question ’Do the major named dietary patterns differ in their effect on patient-important outcomes, and if so which axis carries the difference — the pattern label itself, the shared components common to most evidence-based patterns, total energy/adiposity, or adherence — how large is the difference, how certain, and where is the evidence RCT-grade rather than confounded cohort? Or does the evidence not distinguish the patterns at all?‘ Evidence included 34 sources — 18 gold, 15 high, 1 weak Overall certainty Low (see Rating Certainty of Evidence) Source-selection note 1 source(s) below the gold evidence bar feed this page: Astrup (narrative review, weak). Each labelled by tier; none load-bearing for the core claims. Last updated 2026-09-03 · Independently reviewed: No · Full edit history